SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy > View All News All News Upcoming Events More events are coming soon. > View All Events All Events Latest Presentation May 26, 2023 RBC Healthcare Conference Presentation March 9, 2023 Full-Year Earnings 2022 Presentation January 12, 2023 J.P. Morgan Healthcare Conference Presentation > View All Presentations All Presentations Latest Financial Documents April 19, 2023 Molecular Partners statement regarding Passive Foreign Investment Company status March 9, 2023 Annual Report FY2022 October 27, 2022 Q3 2022 Financial Statement > View All Reports All Annual Report Seth Lewis, SVP Investor Relations and Strategy Contact Seth STAY INFORMED Subscribe to email alerts of your choosing SUBSCRIBE Institutional investors: REQUEST 1-1 / CALL powered by schedulR
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
